fda warning compounded semaglutide october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Semaglutide Patient Safety Updates |

Obesity is a complex condition so many factors contribute to its occurrence (and reoccurrence) over time, and these factors are not the same for all people, says Gudzune

23-25 The FDA-approved indication for weight management use of GLP-1 RAs is a BMI of 30 or higher, or a BMI of 27 or higher with at least 1 other cardiometabolic comorbidity such as type 2 diabetes or hyperlipidemia

Your first defense should always be talking to your doctor before taking new supplements

Ideal Candidates Our Phoenix and Scottsdale program is designed for adults who: Have a BMI of 30 or higher (or 27+ with health conditions like hypertension)

Medicines are vital for keeping blood sugar in check